G1 Therapeutics Stock Price, News & Analysis (NASDAQ:GTHX)

$24.11 +2.10 (+9.54 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$24.11
Today's Range$21.22 - $24.18
52-Week Range$12.04 - $28.67
Volume212,016 shs
Average Volume71,562 shs
Market Capitalization$626.07 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About G1 Therapeutics (NASDAQ:GTHX)

G1 Therapeutics logoG1 Therapeutics, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6. Trilaciclib and G1T38 are designed to be combined and enhance the anti-tumor activity of current therapies. It is also developing G1T48, an oral selective estrogen receptor degrader (SERD) for the treatment of breast cancer. The Company is evaluating trilaciclib in three Phase II clinical trials. G1T38 is being evaluated in combination with Faslodex in a Phase I b/II a trial for patients with estrogen receptor-positive, HER2-negative breast cancer.

Receive GTHX News and Ratings via Email

Sign-up to receive the latest news and ratings for GTHX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:GTHX
CUSIPN/A
Phone919-213-9835

Debt

Debt-to-Equity RatioN/A
Current Ratio8.95%
Quick Ratio11.42%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$3.28 per share
Price / Book7.35

Profitability

Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees31
Outstanding Shares28,440,000

G1 Therapeutics (NASDAQ:GTHX) Frequently Asked Questions

What is G1 Therapeutics' stock symbol?

G1 Therapeutics trades on the NASDAQ under the ticker symbol "GTHX."

How were G1 Therapeutics' earnings last quarter?

G1 Therapeutics Inc (NASDAQ:GTHX) released its quarterly earnings data on Wednesday, February, 21st. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.58) by $0.02. View G1 Therapeutics' Earnings History.

When will G1 Therapeutics make its next earnings announcement?

G1 Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, May, 16th 2018. View Earnings Estimates for G1 Therapeutics.

Where is G1 Therapeutics' stock going? Where will G1 Therapeutics' stock price be in 2018?

5 analysts have issued 1 year target prices for G1 Therapeutics' stock. Their predictions range from $30.00 to $38.00. On average, they expect G1 Therapeutics' stock price to reach $32.80 in the next twelve months. View Analyst Ratings for G1 Therapeutics.

What are Wall Street analysts saying about G1 Therapeutics stock?

Here are some recent quotes from research analysts about G1 Therapeutics stock:

  • 1. According to Zacks Investment Research, "G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel, small-molecule therapies which address significant unmet needs in the treatment of cancer. The company's product pipeline consists of CDK4/6, Trilaciclib (G1T28), G1T38 and G1T48. G1 Therapeutics, Inc. is based in Research Triangle Park, NC. " (2/8/2018)
  • 2. Cowen Inc analysts commented, "G1 Therapeutics reported a Q3 net loss of $16MM and September 30 cash of." (11/8/2017)

Who are some of G1 Therapeutics' key competitors?

Who are G1 Therapeutics' key executives?

G1 Therapeutics' management team includes the folowing people:

  • Seth A. Rudnick M.D., Chairman of the Board (Age 68)
  • Mark A. Velleca Ph.D., M.D., President, Chief Executive Officer, Director (Age 53)
  • Barclay A. Phillips, Chief Financial Officer and Senior Vice President - Corporate Development (Age 55)
  • Jay C. Strum Ph.D., Chief Scientific Officer (Age 53)
  • Jennifer K. Moses, Vice President - Finance and Administration (Age 42)
  • Rajesh K. Malik M.D., Chief Medical Officer (Age 58)
  • Gregory J. Mossinghoff, Chief Business Officer, Secretary (Age 56)
  • Andrew Philip Witty, Director (Age 52)
  • Fredric N. Eshelman Ph.D., Independent Director (Age 68)
  • Glenn P. Muir, Independent Director (Age 58)

When did G1 Therapeutics IPO?

(GTHX) raised $101 million in an IPO on Wednesday, May 17th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and Cowen and Company acted as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.

Who owns G1 Therapeutics stock?

G1 Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Franklin Resources Inc. (5.42%), BlackRock Inc. (2.63%), Emerald Advisers Inc. PA (2.55%), Rock Springs Capital Management LP (0.76%), Geode Capital Management LLC (0.33%) and Chartwell Investment Partners LLC (0.30%). Company insiders that own G1 Therapeutics stock include Clay Thorp, Fredric N Eshelman, Jennifer K Moses, Mark A Velleca, Medimmune Ventures, Inc, Ra Capital Healthcare Fund Lp and Rajesh Malik. View Institutional Ownership Trends for G1 Therapeutics.

Who sold G1 Therapeutics stock? Who is selling G1 Therapeutics stock?

G1 Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Rock Springs Capital Management LP, Emerald Advisers Inc. PA and Chartwell Investment Partners LLC. Company insiders that have sold G1 Therapeutics company stock in the last year include Jennifer K Moses, Mark A Velleca, Medimmune Ventures, Inc and Rajesh Malik. View Insider Buying and Selling for G1 Therapeutics.

Who bought G1 Therapeutics stock? Who is buying G1 Therapeutics stock?

G1 Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Franklin Resources Inc., Two Sigma Investments LP, Goldman Sachs Group Inc., Virtus Fund Advisers LLC, Ellington Management Group LLC, Hodges Capital Management Inc. and Swiss National Bank. Company insiders that have bought G1 Therapeutics stock in the last two years include Clay Thorp, Fredric N Eshelman and Ra Capital Healthcare Fund Lp. View Insider Buying and Selling for G1 Therapeutics.

How do I buy G1 Therapeutics stock?

Shares of G1 Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is G1 Therapeutics' stock price today?

One share of G1 Therapeutics stock can currently be purchased for approximately $24.11.

How big of a company is G1 Therapeutics?

G1 Therapeutics has a market capitalization of $626.07 million. G1 Therapeutics employs 31 workers across the globe.

How can I contact G1 Therapeutics?

G1 Therapeutics' mailing address is 79 T.W. Alexander Drive 4501 Research Commons Suite 100, Research Triangle Park NC, 27709. The company can be reached via phone at 919-213-9835.


MarketBeat Community Rating for G1 Therapeutics (GTHX)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  56 (Vote Outperform)
Underperform Votes:  65 (Vote Underperform)
Total Votes:  121
MarketBeat's community ratings are surveys of what our community members think about G1 Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

G1 Therapeutics (NASDAQ:GTHX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $32.80$31.40$29.75$29.75
Price Target Upside: 70.66% upside63.12% upside33.41% upside137.43% upside

G1 Therapeutics (NASDAQ:GTHX) Consensus Price Target History

Price Target History for G1 Therapeutics (NASDAQ:GTHX)

G1 Therapeutics (NASDAQ:GTHX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/22/2018BTIG ResearchReiterated RatingBuy$38.00HighView Rating Details
2/5/2018JPMorgan Chase & Co.Boost Price Target$30.00HighView Rating Details
11/8/2017CowenReiterated RatingBuyN/AView Rating Details
6/12/2017WedbushInitiated CoverageOutperform$31.00HighView Rating Details
6/12/2017Needham & Company LLCInitiated CoverageBuy -> Buy$34.00HighView Rating Details
(Data available from 2/24/2016 forward)

Earnings

G1 Therapeutics (NASDAQ:GTHX) Earnings History and Estimates Chart

Earnings by Quarter for G1 Therapeutics (NASDAQ:GTHX)

G1 Therapeutics (NASDAQ GTHX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/16/2018        
2/21/2018Q4 2017($0.58)($0.60)ViewN/AView Earnings Details
11/8/2017Q3 2017($0.56)($0.55)ViewN/AView Earnings Details
8/9/20176/30/2017($0.61)($1.09)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

G1 Therapeutics (NASDAQ:GTHX) Earnings Estimates

2018 EPS Consensus Estimate: ($2.33)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.64)($0.64)($0.64)
Q2 20181($0.54)($0.54)($0.54)
Q3 20181($0.56)($0.56)($0.56)
Q4 20181($0.59)($0.59)($0.59)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for G1 Therapeutics (NASDAQ:GTHX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

G1 Therapeutics (NASDAQ GTHX) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 52.01%
Insider Trades by Quarter for G1 Therapeutics (NASDAQ:GTHX)
Institutional Ownership by Quarter for G1 Therapeutics (NASDAQ:GTHX)

G1 Therapeutics (NASDAQ GTHX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/15/2018Rajesh MalikInsiderSell3,776$20.00$75,520.00View SEC Filing  
2/5/2018Jennifer K MosesVPSell750$22.99$17,242.50View SEC Filing  
1/16/2018Rajesh MalikInsiderSell3,776$22.96$86,696.96View SEC Filing  
1/5/2018Jennifer K MosesVPSell750$19.96$14,970.00View SEC Filing  
12/18/2017Mark A VellecaInsiderSell7,500$20.01$150,075.00View SEC Filing  
12/15/2017Medimmune Ventures, Inc.Major ShareholderSell200,000$19.75$3,950,000.00View SEC Filing  
12/1/2017Medimmune Ventures, Inc.Major ShareholderSell133,906$19.75$2,644,643.50View SEC Filing  
11/20/2017Medimmune Ventures, Inc.Major ShareholderSell200,000$20.01$4,002,000.00View SEC Filing  
11/13/2017Fredric N EshelmanDirectorBuy250,000$19.73$4,932,500.00View SEC Filing  
5/22/2017Clay ThorpMajor ShareholderBuy133,333$15.00$1,999,995.00View SEC Filing  
5/22/2017Fredric N EshelmanDirectorBuy300,000$15.00$4,500,000.00View SEC Filing  
5/22/2017Ra Capital Healthcare Fund LpInsiderBuy400,000$15.00$6,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

G1 Therapeutics (NASDAQ GTHX) News Headlines

Source:
DateHeadline
Brokers Issue Forecasts for G1 Therapeutics Incs FY2022 Earnings (GTHX)Brokers Issue Forecasts for G1 Therapeutics Inc's FY2022 Earnings (GTHX)
www.americanbankingnews.com - February 23 at 5:22 PM
BTIG Research Reiterates "Buy" Rating for G1 Therapeutics (GTHX)BTIG Research Reiterates "Buy" Rating for G1 Therapeutics (GTHX)
www.americanbankingnews.com - February 22 at 4:24 PM
G1 Therapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Operational HighlightsG1 Therapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Operational Highlights
finance.yahoo.com - February 21 at 4:31 PM
G1 Therapeutics Inc (GTHX) Insider Rajesh Malik Sells 3,776 SharesG1 Therapeutics Inc (GTHX) Insider Rajesh Malik Sells 3,776 Shares
www.americanbankingnews.com - February 16 at 12:40 PM
G1 Therapeutics (GTHX) Set to Announce Earnings on WednesdayG1 Therapeutics (GTHX) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - February 16 at 12:14 AM
G1 Therapeutics (GTHX) Stock Rating Lowered by Zacks Investment ResearchG1 Therapeutics (GTHX) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - February 8 at 9:08 AM
G1 Therapeutics Inc (GTHX) Given Average Rating of "Buy" by BrokeragesG1 Therapeutics Inc (GTHX) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - February 7 at 3:08 AM
Insider Selling: G1 Therapeutics Inc (GTHX) VP Sells 750 Shares of StockInsider Selling: G1 Therapeutics Inc (GTHX) VP Sells 750 Shares of Stock
www.americanbankingnews.com - February 6 at 12:23 PM
G1 Therapeutics (GTHX) PT Raised to $30.00 at JPMorgan Chase & Co.G1 Therapeutics (GTHX) PT Raised to $30.00 at JPMorgan Chase & Co.
www.americanbankingnews.com - February 5 at 8:42 PM
G1 Therapeutics (GTHX) Downgraded by BidaskClub to HoldG1 Therapeutics (GTHX) Downgraded by BidaskClub to Hold
www.americanbankingnews.com - February 3 at 2:44 PM
 Analysts Expect G1 Therapeutics Inc (GTHX) to Announce -$0.58 EPS Analysts Expect G1 Therapeutics Inc (GTHX) to Announce -$0.58 EPS
www.americanbankingnews.com - January 29 at 8:30 AM
G1 Therapeutics Inc (GTHX) Insider Sells $86,696.96 in StockG1 Therapeutics Inc (GTHX) Insider Sells $86,696.96 in Stock
www.americanbankingnews.com - January 17 at 12:36 PM
G1 Therapeutics Inc (GTHX) Short Interest UpdateG1 Therapeutics Inc (GTHX) Short Interest Update
www.americanbankingnews.com - January 14 at 2:32 AM
G1 Therapeutics Inc (GTHX) Receives Average Recommendation of "Buy" from BrokeragesG1 Therapeutics Inc (GTHX) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - January 13 at 3:32 AM
Jennifer K. Moses Sells 750 Shares of G1 Therapeutics Inc (GTHX) StockJennifer K. Moses Sells 750 Shares of G1 Therapeutics Inc (GTHX) Stock
www.americanbankingnews.com - January 8 at 12:46 PM
G1 Therapeutics to Present at 36th Annual J.P. Morgan Healthcare ConferenceG1 Therapeutics to Present at 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 2 at 9:02 AM
G1 THERAPEUTICS (GTHX) Insider Sells $150,075.00 in StockG1 THERAPEUTICS (GTHX) Insider Sells $150,075.00 in Stock
www.americanbankingnews.com - December 20 at 11:38 AM
G1 THERAPEUTICS (GTHX) Receives Consensus Recommendation of "Buy" from AnalystsG1 THERAPEUTICS (GTHX) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - December 19 at 9:56 PM
G1 THERAPEUTICS (GTHX) Coverage Initiated by Analysts at BTIG ResearchG1 THERAPEUTICS (GTHX) Coverage Initiated by Analysts at BTIG Research
www.americanbankingnews.com - December 19 at 9:02 PM
Insider Selling: G1 THERAPEUTICS (GTHX) Major Shareholder Sells 200,000 Shares of StockInsider Selling: G1 THERAPEUTICS (GTHX) Major Shareholder Sells 200,000 Shares of Stock
www.americanbankingnews.com - December 18 at 8:36 PM
G1 Therapeutics Added to Nasdaq Biotechnology IndexG1 Therapeutics Added to Nasdaq Biotechnology Index
finance.yahoo.com - December 18 at 9:10 AM
Reviewing G1 THERAPEUTICS (GTHX) and Its RivalsReviewing G1 THERAPEUTICS (GTHX) and Its Rivals
www.americanbankingnews.com - December 9 at 1:18 PM
Zacks: G1 THERAPEUTICS (GTHX) Given Average Recommendation of "Strong Buy" by AnalystsZacks: G1 THERAPEUTICS (GTHX) Given Average Recommendation of "Strong Buy" by Analysts
www.americanbankingnews.com - December 9 at 3:36 AM
G1 Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)G1 Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
finance.yahoo.com - December 6 at 5:47 PM
Medimmune Ventures, Inc. Sells 133,906 Shares of G1 THERAPEUTICS (GTHX) StockMedimmune Ventures, Inc. Sells 133,906 Shares of G1 THERAPEUTICS (GTHX) Stock
www.americanbankingnews.com - December 5 at 11:48 AM
G1 THERAPEUTICS (GTHX) Short Interest Down 25.3% in NovemberG1 THERAPEUTICS (GTHX) Short Interest Down 25.3% in November
www.americanbankingnews.com - November 30 at 5:52 AM
G1 Therapeutics and AstraZeneca Enter Clinical Trial Collaboration in Non-Small Cell Lung CancerG1 Therapeutics and AstraZeneca Enter Clinical Trial Collaboration in Non-Small Cell Lung Cancer
finance.yahoo.com - November 28 at 9:19 AM
 Brokerages Set $29.67 Target Price for G1 THERAPEUTICS (GTHX) Brokerages Set $29.67 Target Price for G1 THERAPEUTICS (GTHX)
www.americanbankingnews.com - November 23 at 3:12 PM
Medimmune Ventures, Inc. Sells 200,000 Shares of G1 THERAPEUTICS (GTHX) StockMedimmune Ventures, Inc. Sells 200,000 Shares of G1 THERAPEUTICS (GTHX) Stock
www.americanbankingnews.com - November 22 at 1:36 PM
Insider Buying: G1 THERAPEUTICS (GTHX) Director Buys 250,000 Shares of StockInsider Buying: G1 THERAPEUTICS (GTHX) Director Buys 250,000 Shares of Stock
www.americanbankingnews.com - November 15 at 7:32 PM
Q4 2017 EPS Estimates for G1 THERAPEUTICS Raised by Wedbush (GTHX)Q4 2017 EPS Estimates for G1 THERAPEUTICS Raised by Wedbush (GTHX)
www.americanbankingnews.com - November 13 at 4:52 AM
G1 THERAPEUTICS (GTHX) & MEI Pharma (MEIP) Critical AnalysisG1 THERAPEUTICS (GTHX) & MEI Pharma (MEIP) Critical Analysis
www.americanbankingnews.com - November 13 at 1:46 AM
[$$] Triggering a Debt Bomb[$$] Triggering a Debt Bomb
finance.yahoo.com - November 11 at 8:50 AM
G1 THERAPEUTICSs (GTHX) Buy Rating Reiterated at Cowen and CompanyG1 THERAPEUTICS's (GTHX) Buy Rating Reiterated at Cowen and Company
www.americanbankingnews.com - November 8 at 5:08 PM
G1 Therapeutics to Present at Stifel 2017 Healthcare ConferenceG1 Therapeutics to Present at Stifel 2017 Healthcare Conference
finance.yahoo.com - November 8 at 8:38 AM
G1 Therapeutics Makes Key Executive AppointmentsG1 Therapeutics Makes Key Executive Appointments
finance.yahoo.com - November 8 at 8:38 AM
G1 Therapeutics Reports Third Quarter 2017 Financial Results and Recent Operational HighlightsG1 Therapeutics Reports Third Quarter 2017 Financial Results and Recent Operational Highlights
finance.yahoo.com - November 8 at 8:38 AM
Zacks: G1 THERAPEUTICS (GTHX) Given $29.67 Average Price Target by BrokeragesZacks: G1 THERAPEUTICS (GTHX) Given $29.67 Average Price Target by Brokerages
www.americanbankingnews.com - November 7 at 10:59 AM
G1 Therapeutics Announces Publication in Cancer Discovery Demonstrating That CDK4/6 Inhibition Enhances the Anti-Tumor T Cell ResponseG1 Therapeutics Announces Publication in Cancer Discovery Demonstrating That CDK4/6 Inhibition Enhances the Anti-Tumor T Cell Response
finance.yahoo.com - November 7 at 2:03 AM
G1 THERAPEUTICSs (GTHX) Lock-Up Period Will Expire  on November 13thG1 THERAPEUTICS's (GTHX) Lock-Up Period Will Expire on November 13th
www.americanbankingnews.com - November 6 at 1:28 AM
Oversold Conditions For G1 Therapeutics (GTHX)Oversold Conditions For G1 Therapeutics (GTHX)
www.thestreet.com - October 25 at 3:14 AM
 Analysts Set $29.67 Target Price for G1 Therapeutics Inc (GTHX) Analysts Set $29.67 Target Price for G1 Therapeutics Inc (GTHX)
www.americanbankingnews.com - October 23 at 10:58 AM
 G1 THERAPEUTICS (GTHX) Given $29.67 Consensus Price Target by Analysts G1 THERAPEUTICS (GTHX) Given $29.67 Consensus Price Target by Analysts
www.americanbankingnews.com - October 16 at 12:34 PM
G1 THERAPEUTICS (GTHX) Sees Significant Growth in Short InterestG1 THERAPEUTICS (GTHX) Sees Significant Growth in Short Interest
www.americanbankingnews.com - October 14 at 1:14 AM
 G1 THERAPEUTICS (GTHX) Given $29.67 Average Target Price by Analysts G1 THERAPEUTICS (GTHX) Given $29.67 Average Target Price by Analysts
www.americanbankingnews.com - October 7 at 10:28 AM
Following IPO, Dova puts lead drug in FDA’s handsFollowing IPO, Dova puts lead drug in FDA’s hands
www.bizjournals.com - September 27 at 10:17 PM
Why Hatteras Venture Partners brought on Andrew WittyWhy Hatteras Venture Partners brought on Andrew Witty
www.bizjournals.com - September 20 at 5:22 AM
G1 Therapeutics Added to Russell 2000®, 3000® and Microcap® IndexesG1 Therapeutics Added to Russell 2000®, 3000® and Microcap® Indexes
finance.yahoo.com - September 18 at 6:48 PM
 Analysts Set $29.67 Target Price for G1 THERAPEUTICS (GTHX) Analysts Set $29.67 Target Price for G1 THERAPEUTICS (GTHX)
www.americanbankingnews.com - September 11 at 4:42 AM
SRPT Walks The Talk, VSTM Grows, PULM Pulls Back, Smooth Sailing For VYGRSRPT Walks The Talk, VSTM Grows, PULM Pulls Back, Smooth Sailing For VYGR
www.nasdaq.com - September 7 at 5:19 AM

SEC Filings

G1 Therapeutics (NASDAQ:GTHX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

G1 Therapeutics (NASDAQ:GTHX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

G1 Therapeutics (NASDAQ GTHX) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.